Roche logo

Roche

RHHBY | OTC
Chart Builder DCF Calculator
$60.98
+$0.68 (+1.13%)
At close: Nov 16, 2026, 3:59 PM ET
$60.95
-$0.03 (-0.05%)
After-hours: Nov 16, 2026, 4:00 PM ET
+1.13%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
52.2
Fundamentals Average
Market Sentiment Neutral
Moat Wide
Sector Rank #235/1021 (Top 23%)

Why Price Moved

24 days ago
+2.62%

Shares are trading higher after Roche announced po...

Key Statistics

Market Data

Market Cap $390.61B
1D Range
60.81 61.27
52W Range
44.58 61.39

Valuation (TTM)

PE 25.29
PB 9.66
EV/EBITDA 15.48

Valuation (NTM)

Forward PE 20.27
Forward PEG 6.23
Price Target $63.00
Loading financial charts...

Profile

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international ...

Sector Healthcare
Employees 103,249
IPO Date Aug 20, 2003
Fiscal Year n/a

Latest News

FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

8 hours ago · globenewswire.com

FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
US FDA approves Roche's oral treatment for advanced breast cancer

9 hours ago · reuters.com

US FDA approves Roche's oral treatment for advanced breast cancer
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories

16 hours ago · prnewswire.com

Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Chances of Jensen Huang returning to Nvidia 'very slim': David Roche

18 hours ago · youtube.com

Chances of Jensen Huang returning to Nvidia 'very slim': David Roche

David Roche, President and Global Strategist at Quantum Strategy says he's out of the AI trade because it's a bubble and that he "wouldn't touch NVIDIA with a barge pole". He adds Nvidia's growth outlook is also weakening, citing Jensen Huang's role, its Taiwan ties and lost access to China, and expects the shares to settle below current levels.

Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer

18 hours ago · businesswire.com

Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems

6 days ago · businesswire.com

Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

15 days ago · prnewswire.com

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Roche: Valuation Leaves Limited Upside

19 days ago · seekingalpha.com

Roche: Valuation Leaves Limited Upside
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

21 days ago · globenewswire.com

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

22 days ago · globenewswire.com

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

Earnings

Next Earnings
Jan 28, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.